Molecular Infectious Disease Testing Market Size Worth USD 34.73 Billion by 2034 | CAGR: 13.5%

The molecular infectious disease testing market size is expected to reach USD 34.73 billion by 2034, according to a new study by Polaris Market Research. The report “Molecular Infectious Disease Testing Market Share, Size, Trends, Industry Analysis Report: By Product & Service, Type (Multiplex Testing and Singleplex Testing), Test Type, Disease, Technology, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Molecular infectious disease testing refers to advanced diagnostic techniques that detect and analyze the genetic material of pathogens to enable precise and early disease identification. A major molecular infectious disease testing market trend is the increasing adoption of multiplex molecular diagnostics, which allow the simultaneous detection of multiple pathogens in a single test. This advancement improves diagnostic efficiency, reduces turnaround time, and improves clinical decision-making. The growing demand for rapid and wide diagnostic solutions, particularly in acute care settings, is further driving the integration of multiplex assays into routine molecular testing, strengthening their role in infectious disease management.

Do you have questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/molecular-infectious-disease-testing-market/request-for-sample

Another major trend shaping the molecular infectious disease testing market demand is the rising integration of automation and artificial intelligence (AI) in diagnostic workflows. Automated molecular testing platforms are improving laboratory efficiency, minimizing human errors, and improving scalability to meet the increasing testing demand. AI-driven data analysis is further refining result interpretation, facilitating more accurate diagnoses and predictive analytics. The combination of automation and AI is streamlining molecular diagnostics, making testing more accessible and reliable across various healthcare settings, thereby accelerating molecular infectious disease testing market growth.

Top of FormMolecular Infectious Disease Testing Market Report Highlights

• In terms of disease, the sexually transmitted disease (STD) segment led the molecular infectious disease testing market share in 2024, driven by the rising incidence of STIs and the growing need for precise and early diagnostic solutions.
• Based on product & service, the reagents & kits segment is anticipated to experience the most rapid growth in the market during the forecast period, fueled by the increasing utilization of molecular diagnostic tests across various healthcare settings.
• North America emerged as the leading region in the global molecular infectious disease testing market revenue share in 2024, attributed to its well-developed healthcare infrastructure, high adoption of advanced diagnostic technologies, and a robust regulatory framework supporting molecular testing.
• The molecular infectious disease testing market in Asia Pacific is expected to witness the highest growth rate during the forecast period, driven by expanding healthcare investments, greater awareness of early disease detection, and a rising prevalence of infectious diseases.
• A few global key market players include Abbott; Danaher Corporation; bioMérieux SA; F. Hoffmann-La Roche Ltd; Bio-Rad Laboratories, Inc.; Agilent Technologies, Inc.; Becton, Dickinson and Company; Hologic, Inc. (Gen-Probe); Illumina, Inc., Grifols S.A.; Qiagen; Siemens Healthineers AG; Sysmex Corporation; Bruker Corporation; and Thermo Fisher Scientific.

Polaris Market Research has segmented the molecular infectious disease testing market report on the basis of product & service, type, test type, disease, technology, end user, and region:

By Product & Service Outlook (Revenue, USD Billion, 2020–2034)

• Reagents & Kits
• Instruments
• Services & Software

By Type Outlook (Revenue, USD Billion, 2020–2034)

• Multiplex Testing
• Singleplex Testing

By Test Type Outlook (Revenue, USD Billion, 2020–2034)

• Laboratory Tests
• Point-of-Care Tests

By Disease Outlook (Revenue, USD Billion, 2020–2034)

• Respiratory Infectious Diseases
• Gastrointestinal Infectious Diseases
• Sexually Transmitted Diseases
• Hospital-Acquired Infections
• Vaginitis
• Meningitis
• Vector-Borne Diseases
• Other Infectious Diseases

By Technology Outlook (Revenue, USD Billion, 2020–2034)

• Polymerase Chain Reaction
• Isothermal Nucleic Acid Amplification Technology
• DNA-Sequencing & Next-Generation Sequencing
• In-Situ Hybridization
• DNA Microarrays
• Others

By End User Outlook (Revenue, USD Billion, 2020–2034)

• Diagnostic Laboratories
• Hospitals & Clinics
• Others

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Vietnam
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Molecular Infectious Disease Testing Market Report Scope